Vertex's Sales Plunge 64% as It Refocuses Its Pipeline on Cystic Fibrosis Therapies

Kalydeco sales soar, but Vertex abandons its hepatitis C drug Incivek, causing revenue and EPS to tumble.

May 1, 2014 at 5:46PM

Large-cap biopharmaceutical company Vertex Pharmaceuticals (NASDAQ:VRTX) is right in the middle of a product transition from a dual focus on hepatitis C and cystic fibrosis to a full focus on cystic fibrosis – and its first-quarter results demonstrate those struggles.

For the quarter, Vertex reported a 64% decline in revenue, to $118.5 million, despite revenue from cystic fibrosis drug Kalydeco soaring 61%, to $99.5 million. Its huge revenue drop came from Vertex pulling away from marketing its hepatitis C therapy Incivek, which saw product sales fall to just $3.9 million. (Keep in mind this was the previous fastest-growing drug to ever reach $1 billion in sales.) Comparatively, Incivek produced $205.6 million in sales in the first-quarter last year.

The good news here is that focusing solely on cystic fibrosis dropped Vertex's operating expenses to $334.8 million from $766.7 million in the prior-year period, although research and development expenses rose 10%.

Vertex's adjusted bottom-line results reversed course from a $5.7 million profit, or $0.03 per share, in the year-ago period to a huge $151.4 million loss, or $0.65 per share. Vertex blamed the loss on reduced sales of Incivek and lower royalty revenue from Incivo. Vertex also ended the quarter with $1.32 billion in cash.

Looking ahead, Vertex is forecasting full-year revenue of $520 million-$550 million, excluding revenue from Incivek and its Incivo royalties, with Kalydeco revenue of $470 million-$500 million. Operating expenses are anticipated to be in the $890 million-$930 million range.

Subsequent to its earnings release, Vertex also announced that the addition of VX-661 to Kalydeco improves lung function in cystic fibrosis patients who are heterozygous to the F508del and G551D mutations in a phase 2 proof-of-concept study. Treatment involving this combo produced a mean within-group relative improvement in lung function of 7.3%.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool recommends Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers